Aura Bio rises on FDA fast track tag for bladder cancer treatment

Aura Biosciences

30/06/2022 15:30

** Shares of Aura Biosciences  AURA.O  rise 3.5% to $13
    ** AURA says FDA has granted Fast Track designation to its
lead drug candidate, belzupacap sarotalocan, for the treatment
of a type of bladder cancer  urn:newsml:reuters.com:*:nBw6YRM0Xa
    ** FDA's fast-track tag is intended to speed up review of
drugs for the treatment of serious or life threatening diseases;
benefits include more frequent interactions with the agency
    ** AURA's drug consists of a virus-like particle combined
with an anti-cancer agent designed to selectively target and
destroy cancer cells
    ** Stock down 23% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))